硼替佐米
泊马度胺
医学
多发性骨髓瘤
化疗
中枢神经系统
肿瘤科
放射治疗
疾病
内科学
药理学
作者
Alessandro Gozzetti,Alfonso Cerase
出处
期刊:Central nervous system agents in medicinal chemistry
[Bentham Science]
日期:2014-11-20
卷期号:14 (1): 23-27
被引量:36
标识
DOI:10.2174/1871524914999140818111514
摘要
Central nervous system localization of multiple myeloma (CNS-MM) accounts for about 1% of all MM. Treatment is still unsatisfactory. Many treatments have been described in the literature: chemotherapy (CHT), intrathecal therapy (IT), and radiotherapy (RT), with survivals reported between one month and six months. Recent drugs such as the immunomodulatory drugs (IMiDs) and proteasome inhibitors (bortezomib) have changed the treatment of patients with MM, both younger and older, with a significant improvement in response and survival. The activity of new drugs in CNSMM has been reported but is still not well known. Bortezomib does not cross the blood brain barrier (BBB), and IMID's seem to have only a minimal crossover. The role of novel agents in CNS MM management will be discussed as well as the potential role of other new immunomodulatory drugs (pomalidomide) and proteasome inhibitors that seem to cross the BBB and hold promise into the treatment of this rare and still incurable localization of the disease. Keywords: Bortezomib, chemotherapy, CNS, extramedullary myeloma, IMID's, new agents.
科研通智能强力驱动
Strongly Powered by AbleSci AI